focus -WSS

focus

author：comprehensive 2025-09-04 02:26:26 - browse：17

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Appeals court upholds limits to abortion pill

WSS

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Appeals court upholds limits to abortion pill

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

How to make AI work for medicine

What do new weight loss drugs mean for bariatric surgery?

hotspot

focus

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

Study says nonprofit hospitals fall short in charity care spending

Virginia high school admissions case could be legal follow

Neuroscience startup Neumora files for IPO

Dobbs anniversary: the lost opportunity of abortion as health care

NYU Langone launches private ChatGPT for its health care data

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare explains how it will choose drugs for negotiation

Bright Health sells Medicare Advantage business to Molina

FDA panel gives mixed vote on blood pressure devices

knowledge

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Merck drug for rare lung condition set for approval in U.S.

Patient advocates debate FDA's accelerated approval process

Why more medical students aren't specializing in primary care

How Long Island became the ‘eugenics capital of the world’

explore

leisure time

focus

Wikipedia